Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
2001 3
2002 1
2003 1
2004 5
2005 5
2006 7
2007 5
2008 6
2009 4
2010 4
2011 6
2012 7
2013 4
2014 11
2015 8
2016 11
2017 15
2018 16
2019 25
2020 31
2021 36
2022 33
2023 39
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Results by year

Filters applied: . Clear all
Page 1
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, Johnston SRD, Martin M, Rastogi P, Harbeck N, Shahir A, Wei R, André V, Rugo HS, O'Shaughnessy J. Goetz MP, et al. Among authors: guarneri v. NPJ Breast Cancer. 2024 Apr 26;10(1):34. doi: 10.1038/s41523-024-00639-1. NPJ Breast Cancer. 2024. PMID: 38671001 Free PMC article.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A, Macerelli M, Polo V, Pilotto S, Santarpia M, Cumerlato E, Da Ros V, Targato G, Bortolami A, Bonanno L, Ferro A, Dal Maso A, Frega S, Guarneri V. Pasello G, et al. Among authors: guarneri v. Oncologist. 2024 Mar 23:oyae043. doi: 10.1093/oncolo/oyae043. Online ahead of print. Oncologist. 2024. PMID: 38520745 Free article.
Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: guarneri v. Cancer Treat Rev. 2024 Apr;125:102714. doi: 10.1016/j.ctrv.2024.102714. Epub 2024 Mar 16. Cancer Treat Rev. 2024. PMID: 38493647 No abstract available.
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients.
Miglietta F, Pontolillo L, De Angelis C, Caputo R, Marino M, Bria E, Di Rienzo R, Verrazzo A, Buonerba C, Tortora G, Di Lorenzo G, Del Mastro L, Giuliano M, Montemurro F, Puglisi F, Guarneri V, De Laurentiis M, Scafuri L, Arpino G. Miglietta F, et al. Among authors: guarneri v. Breast. 2024 Mar 9;75:103713. doi: 10.1016/j.breast.2024.103713. Online ahead of print. Breast. 2024. PMID: 38493590 Free PMC article.
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G, Fabricio ASC, Del Bianco P, Salizzato V, Favaretto A, Piccin L, Zustovich F, Fabozzi A, De Rossi C, Pigozzo J, De Nuzzo M, Cappelletto E, Bonanno L, Palleschi D, De Salvo GL, Guarneri V, Gion M, Chiarion-Sileni V. Pasello G, et al. Among authors: guarneri v. J Transl Med. 2024 Mar 5;22(1):242. doi: 10.1186/s12967-024-04920-6. J Transl Med. 2024. PMID: 38443899 Free PMC article.
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.
Ferro A, Marinato GM, Mulargiu C, Marino M, Pasello G, Guarneri V, Bonanno L. Ferro A, et al. Among authors: guarneri v. Crit Rev Oncol Hematol. 2024 Apr;196:104295. doi: 10.1016/j.critrevonc.2024.104295. Epub 2024 Feb 20. Crit Rev Oncol Hematol. 2024. PMID: 38382773 Free article. Review.
279 results